双鹭药业
(002038)
| 流通市值：57.90亿 | | | 总市值：69.86亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 328,747,917.07 | 411,958,243.66 | 433,638,552 | 670,983,014.82 |
| 应收票据及应收账款 | 100,483,666.91 | 102,965,551.13 | 114,670,019.55 | 154,045,649.68 |
| 应收账款 | 100,483,666.91 | 102,965,551.13 | 114,670,019.55 | 154,045,649.68 |
| 应收款项融资 | - | 2,822,933.53 | 771,658.01 | 852,673.01 |
| 预付款项 | 153,479,508.72 | 121,155,659.03 | 114,175,239.49 | 118,677,031.3 |
| 其他应收款合计 | 15,223,716.54 | 15,647,268.06 | 22,216,856.37 | 15,539,804.73 |
| 存货 | 403,254,298.06 | 246,333,789.57 | 236,842,314.19 | 178,060,203.85 |
| 一年内到期的非流动资产 | 328,251,388.9 | 325,713,888.89 | - | - |
| 其他流动资产 | 776,260,991.85 | 781,386,164.26 | 794,860,395.27 | 786,261,927.44 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,561,788,777.04 | 2,488,838,965.65 | 2,204,724,372.87 | 2,415,088,082.81 |
| 非流动资产: | | | | |
| 长期股权投资 | 954,827,731.35 | 951,933,309.68 | 953,926,287.88 | 913,622,554.54 |
| 其他非流动金融资产 | 279,837,831.19 | 279,545,423.72 | 275,764,986.92 | 275,813,045.72 |
| 投资性房地产 | 12,949,974.39 | 13,176,406.14 | 13,402,837.89 | 13,629,269.64 |
| 固定资产 | 413,163,165.64 | 419,321,790.24 | 422,275,232.36 | 427,271,815.75 |
| 在建工程 | 99,844,535.09 | 94,922,038.39 | 83,292,668.13 | 65,443,390.34 |
| 无形资产 | 713,137,683.23 | 678,581,445.8 | 642,984,295.95 | 670,587,642.94 |
| 开发支出 | 479,761,974.97 | 517,283,516.42 | 496,091,641.11 | 480,602,440.28 |
| 长期待摊费用 | 1,718,700.9 | 1,718,700.9 | 1,858,170.98 | 1,858,170.98 |
| 递延所得税资产 | 65,836,193.3 | 69,522,944.42 | - | - |
| 其他非流动资产 | 481,836,271.96 | 464,174,777.38 | 817,312,944.18 | 827,297,231.22 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,502,914,062.02 | 3,490,180,353.09 | 3,706,909,065.4 | 3,676,125,561.41 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 6,064,702,839.06 | 5,979,019,318.74 | 5,911,633,438.27 | 6,091,213,644.22 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 139,278,548.4 | 122,285,265.92 | 98,871,063.9 | 86,323,583.58 |
| 其中：应付票据 | 10,538,577.6 | 1,260,000 | 1,260,000 | - |
| 应付账款 | 128,739,970.8 | 121,025,265.92 | 97,611,063.9 | 86,323,583.58 |
| 预收款项 | 110,822.8 | 25,830.7 | 15,987,770.68 | 108,000 |
| 合同负债 | 106,387,042.1 | 70,506,152.62 | 11,853,735.2 | 14,225,584.53 |
| 应付职工薪酬 | 37,100,791.91 | 42,948,812.36 | 32,569,394.75 | 31,449,018.97 |
| 应交税费 | 2,573,778.48 | 3,486,281.89 | 3,981,896.14 | 8,703,196.5 |
| 其他应付款合计 | 43,754,567.11 | 47,598,720.46 | 39,137,945.58 | 36,566,404.1 |
| 其他流动负债 | 4,789,340.12 | 2,554,056.36 | 2,157,419.51 | 1,097,514.54 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 333,994,890.92 | 289,405,120.31 | 204,559,225.76 | 178,473,302.22 |
| 非流动负债: | | | | |
| 递延收益 | 41,166,185.23 | 43,996,123.1 | 44,170,123.1 | 44,165,123.1 |
| 递延所得税负债 | 63,276,340.2 | 64,969,835.95 | 24,714,961.3 | 29,753,564.55 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 104,442,525.43 | 108,965,959.05 | 68,885,084.4 | 73,918,687.65 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 438,437,416.35 | 398,371,079.36 | 273,444,310.16 | 252,391,989.87 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 |
| 资本公积 | 49,615,655.87 | 49,615,655.87 | 49,615,655.87 | 49,615,655.87 |
| 其他综合收益 | 13,474,826.25 | 13,474,826.25 | 13,474,826.25 | 13,474,826.25 |
| 盈余公积 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 |
| 未分配利润 | 3,895,565,435.16 | 3,849,597,029.54 | 3,906,927,106.17 | 4,107,355,188.61 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 5,618,416,348.02 | 5,572,447,942.4 | 5,629,778,019.03 | 5,830,206,101.47 |
| 少数股东权益 | 7,849,074.69 | 8,200,296.98 | 8,411,109.08 | 8,615,552.88 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 5,626,265,422.71 | 5,580,648,239.38 | 5,638,189,128.11 | 5,838,821,654.35 |
| 负债和股东权益合计 | 6,064,702,839.06 | 5,979,019,318.74 | 5,911,633,438.27 | 6,091,213,644.22 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-26 | 2024-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |